Viridian’s Lumvoa approval breaks Tepezza’s TED monopoly. Inside the label, Phase 3 data, safety risks, payer hurdles and ...
FDA Issues CRL to Sobi for NASP in Uncontrolled Gout, but the letter did not attack the clinical case. It attacked ...
SigHT is formally a long-term observational study. Strategically, its timing points to something larger: Tanabe is building a ...
Revolution Medicines built a $4.3B liquidity wall around daraxonrasib. Inside its Phase 3 data, Royalty Pharma terms, ...
Four months after FDA refused to file Moderna’s application, its vaccine advisers unanimously supported its benefit-risk profile in adults aged 50–64 and again in adults aged 65 and older. Same ...
Viridian’s Lumvoa Broke Tepezza’s Monopoly. Now Viridian Has to Prove It Can Sell | Witfire Elite View Witfire Elite Competitive Strategy Case Studies Launch Execution Long Read Pharma Market Case ...
The pharmaceutical business is no longer a small product-driven market. It is becoming one of the most strategic global industries. IQVIA has projected that global medicine spending may reach nearly ...
Welcome to WordPress. This is your first post. Edit or delete it, then start writing!
The Middle East conflict is now moving directly into pharma boardroom risk. Oil-market stress has intensified, with Vitol’s Bahrain chief warning that the market may still be underpricing the impact ...
The Pharma Tariff War: How US Drug Pricing Pressure Is Forcing Big Pharma to Rewrite Global Strategy
A data-rich pharma business case study on how US tariff pressure, drug pricing policy, domestic manufacturing demands, and global supply-chain politics are reshaping Big Pharma strategy. The latest ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results